Patents Assigned to Mochida Pharmaceutical Co., Ltd.
  • NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVE
    Publication number: 20190023657
    Abstract: The present invention aims to provide a compound having a TrkA inhibitory action, a pharmaceutically acceptable salt thereof, or a solvate thereof, a pharmaceutical composition containing the same as an active ingredient, and a preventive and/or therapeutic agent for medicinal use, in particular for a disease in which TrkA in involved (pain, cancers, inflammation/inflammatory diseases, allergic diseases, skin diseases, neurodegenerative diseases, infectious diseases, Sjogren's syndrome, endometriosis, renal diseases, osteoporosis, and the like).
    Type: Application
    Filed: September 21, 2018
    Publication date: January 24, 2019
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Fumihiko SAITOH, Hiroshi NAGASUE
  • Pyrazole derivative manufacturing method
    Patent number: 10174025
    Abstract: The present invention provides a method for manufacturing a compound represented by formula (I). With this method, provided are a method for manufacturing a 4-heteroaryl-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1H-pyrazole-5-carboxylic acid amide derivative; and an intermediate for this manufacturing method.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: January 8, 2019
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Tsutomu Satoh, Takashi Kudoh, Tetsuo Iwama
  • SELF-EMULSIFYING COMPOSITION OF w3 FATTY ACID
    Publication number: 20180369185
    Abstract: This invention provides a self-emulsifying composition comprising 50 to 95% by weight in total of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; and 5 to 50% by weight of an emulsifier having a hydrophilic lipophilic balance of at least 10. The composition has no or reduced ethanol content, and exhibits excellent self-emulsifying property, dispersibility in the composition, emulsion stability, and absorption property. The composition is adapted for use as a drug.
    Type: Application
    Filed: August 29, 2018
    Publication date: December 27, 2018
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Hirosato FUJII, Motoo YAMAGATA
  • CRYSTAL OF A HETEROCYCLIDENE ACETAMIDE DERIVATIVE
    Publication number: 20180346436
    Abstract: The present invention provides a type I crystal of (E)-2-(7-trifluoromethyl-chroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide having excellent TRPV1 antagonistic activity, a drug and a pharmaceutical composition containing this crystal, and a method for producing the crystal. The present invention provides a type I crystal of (E)-2-(7-trifluoromethyl-chroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide that is excellent in at least one feature selected from the group consisting of storage stability, photostability and thermodynamic stability, that can be preferably obtained with industrially high reproducibility, yield and purity, and that is useful as a crystal of an active pharmaceutical ingredient.
    Type: Application
    Filed: May 30, 2018
    Publication date: December 6, 2018
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventor: Tsutomu SATOH
  • FREEZE-DRIED ALGINIC ACID PREPARATION
    Publication number: 20180338921
    Abstract: The present invention provides: a freeze-dried composition which comprises (a) a monovalent metal alginate and (b) a salt selected from a monovalent metal salt and an ammonium salt; and a method of producing a freeze-dried monovalent metal alginate composition which comprises the steps of freezing an aqueous solution formed by dissolving at least the component (a) and the component (b), performing first drying, and then performing second drying as desired to reduce a water content to 3% by mass or less. This is a freeze-dried monovalent metal alginate composition with suppressed viscosity decrease with the lapse of time.
    Type: Application
    Filed: September 6, 2016
    Publication date: November 29, 2018
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Shuichi ENDO, Naoya YOSHIOKA
  • Composition containing eicosapentaenoic acid alkyl ester, and method for producing same
    Patent number: 10105340
    Abstract: Provided are: a composition containing 96-99 area % of eicosapentaenoic acid alkyl ester, the composition having an arachidonic acid alkyl ester content of 0.7 area % or less, and an eicosapentaenoic-acid-alkyl-ester mono-trans isomer content of 2.5 area % or less; and a method for producing a composition containing a high concentration of eicosapentaenoic acid alkyl ester, the method including performing precision distillation on a composition containing eicosapentaenoic acid alkyl ester, obtained by alkyl esterification of a raw material oil containing eicosapentaenoic acid, under a vacuum of 0.2 Ton or lower and a temperature of 190° C. or lower in the entire column, and performing a concentration treatment on the precision-distilled composition using chromatography.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: October 23, 2018
    Assignees: NIPPON SUISAN KAISHA, LTD., MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Nobushige Doisaki, Shingo Arato, Takuro Fukae
  • Self-emulsifying composition of ?3 fatty acid
    Patent number: 10092536
    Abstract: This invention provides a self-emulsifying composition comprising 50 to 95% by weight in total of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; and 5 to 50% by weight of an emulsifier having a hydrophilic lipophilic balance of at least 10. The composition has no or reduced ethanol content, and exhibits excellent self-emulsifying property, dispersibility in the composition, emulsion stability, and absorption property. The composition is adapted for use as a drug.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: October 9, 2018
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Hirosato Fujii, Motoo Yamagata
  • Compositions and methods for treating non-alcoholic steatohepatitis
    Patent number: 10058528
    Abstract: Compositions and method are disclosed comprising ethyl icosapentate for use in treatment of non-alcoholic steatohepatis (NASH).
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: August 28, 2018
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Kiyoshi Mizuguchi, Tsuyoshi Harada, Atsushi Osada, Hiroyuki Kawano, Masayuki Ichioka
  • SPECIFICALLY PURIFIED ANTI-PRESEPSIN ANTIBODY
    Publication number: 20180237537
    Abstract: The present invention provides anti-presepsin polyclonal antibodies specifically binding to a peptide comprising an amino acid sequence of SEQ ID NO: 1. As a result, anti-presepsin polyclonal antibodies which have less variation in measured values between lot-to-lot differences of antibodies compared to S68 antibodies and thus suitable anti-presepsin polyclonal antibodies for presepsin measurement are provided.
    Type: Application
    Filed: August 25, 2015
    Publication date: August 23, 2018
    Applicant: Mochida Pharmaceutical Co., Ltd.
    Inventor: Kamon SHIRAKAWA
  • Diagnosis of respiratory tract infectious disease using urine specimens
    Patent number: 10054585
    Abstract: Methods for detecting respiratory infection associated with bacterial infection are described, in which the values of soluble CD14 antigen subtype (“sCD14-ST”) in the urine sample can be used to select a patient with a respiratory infection to whom antibiotic can be beneficially administered. The methods of this disclosure can also be used to determine the timing for ending administration of the antibiotic to the patient with respiratory infection associated with bacterial infection.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: August 21, 2018
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventor: Kamon Shirakawa
  • ISOTHIAZOLE DERIVATIVE
    Publication number: 20180228776
    Abstract: The present invention provides a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof or a solvate of these. A compound having Nrf2 activation ability is provided by the present invention.
    Type: Application
    Filed: August 10, 2016
    Publication date: August 16, 2018
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Fumihiko SAITOH, Tomoyuki KAMINO, Motoi NAKAHARA
  • NOVEL ANTI-PRESEPSIN ANTIBODY
    Publication number: 20180201688
    Abstract: The present invention provides methods and compositions for determining sepsis in an individual. Specifically, the present invention provides for antibodies of fragments thereof that specifically bind to presepsin. The antibodies of the present invention may be monoclonal antibodies, and they may specifically bind to a particular epitope of presepsin. The present invention further provides methods of using such antibodies to determine whether an individual has sepsis, and kits comprising the disclosed antibodies.
    Type: Application
    Filed: March 8, 2018
    Publication date: July 19, 2018
    Applicant: Mochida Pharmaceutical Co., Ltd.
    Inventor: Kamon SHIRAKAWA
  • Diagnosis of respiratory tract infectious disease using blood specimens
    Patent number: 10024869
    Abstract: According to the methods for detecting respiratory infection associated with bacterial infection of the present invention, the values of soluble CD14 antigen subtype (“sCD14-ST”) in the blood sample can be used to select a patient with a respiratory infection to whom the antibiotic can be administered. The methods of this disclosure can also be used to determine the timing for ending administration of the antibiotic to the patient with respiratory infection.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: July 17, 2018
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventor: Kamon Shirakawa
  • Factor IXa inhibitors
    Patent number: 9969724
    Abstract: In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: May 15, 2018
    Assignees: Merck Sharp & Dohme Corp., Mochida Pharmaceutical Co., Ltd.
    Inventors: Isao Sakurada, Tomokazu Hirabayashi, Yoshitaka Maeda, Hiroshi Nagasue, Takashi Mizuno, Jiayi Xu, Ting Zhang, Cameron Smith, Dann Parker
  • Anti-presepsin antibody
    Patent number: 9951142
    Abstract: The present invention provides methods and compositions for determining sepsis in an individual. Specifically, the present invention provides for antibodies of fragments thereof that specifically bind to presepsin. The antibodies of the present invention may be monoclonal antibodies, and they may specifically bind to a particular epitope of presepsin. The present invention further provides methods of using such antibodies to determine whether an individual has sepsis, and kits comprising the disclosed antibodies.
    Type: Grant
    Filed: February 25, 2015
    Date of Patent: April 24, 2018
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventor: Kamon Shirakawa
  • PYRAZOLE DERIVATIVE MANUFACTURING METHOD
    Publication number: 20180099964
    Abstract: The present invention provides a method for manufacturing a compound represented by formula (I). With this method, provided are a method for manufacturing a 4-heteroaryl-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1H-pyrazole-5-carboxylic acid amide derivative; and an intermediate for this manufacturing method.
    Type: Application
    Filed: December 13, 2017
    Publication date: April 12, 2018
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Tsutomu SATOH, Takashi KUDOH, Tetsuo IWAMA
  • Composition containing eicosapentaenoic acid alkyl ester, and method for producing same
    Patent number: 9918953
    Abstract: Provided are: an eicosapentaenoic acid alkyl ester-ontaining composition which comprises 96-99 area % of an eicosapentaenoic acid alkyl ester, wherein the content of an arachidonic acid alkyl ester is 0.7 area % or less, and the content of mono-trans forms of the eicosapentaenoic acid alkyl ester is 2.5 area % or less; a method for producing a high-concentration eicosapentaenoic acid alkyl ester-containing composition, which comprises performing rectification on an eicosapentaenoic acid alkyl ester-containing composition with the degree of vacuum being 0.2 Torr or less and at a whole-column temperature 190° C. or less, and performing a concentration treatment on the rectified composition using chromatography, the eicosapentaenoic acid alkyl ester-containing composition being obtained by alkyl esterifying a feed oil containing eicosapentaenoic acid.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: March 20, 2018
    Assignees: NIPPON SUISAN KAISHA, LTD., MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Nobushige Doisaki, Shingo Arato, Takuro Fukae
  • Factor IXa inhibitors
    Patent number: 9914727
    Abstract: The present invention provides compounds of Formula (I) and pharmaceutical compositions comprising compounds of Formula I, and methods for using compounds of Formula I for treating or preventing thromboses, embolisms, hypercoaguability or fibrotic changes.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: March 13, 2018
    Assignees: Merck Sharp & Dohme Corp., Mochida Pharmaceutical Co., Ltd.
    Inventors: Cameron James Smith, John Qiang Tan, Ting Zhang, James Balkovec, William John Greenlee, Liangqin Guo, Yi-Heng Chen, Yili Chen, Samuel Chackalamannil, Tomokazu Hirabayashi, Mika Sekioka
  • Pyrazole derivative manufacturing method
    Patent number: 9902723
    Abstract: The present invention provides a method for manufacturing a compound represented by formula (I). With this method, provided is a method for manufacturing a 4-substituted-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1H-pyrazole-5-carboxylic acid amide derivative; or an intermediate for this manufacturing method.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: February 27, 2018
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Tsutomu Satoh, Takashi Kudoh, Tetsuo Iwama
  • Compositions and methods for treating non-alcoholic steatohepatitis
    Patent number: 9889108
    Abstract: The disclosure provides for a method for treating a fatty liver disease or disorder in a subject in need thereof, comprising selecting a subject having or suspected of having a fatty liver disease or disorder, wherein the subject is non diabetic, pre-diabetic, mildly diabetic; has normal or substantially normal biliary tract function; or has non or early stage hepatocyte apoptosis; and administering a therapeutically effective amount of a pharmaceutical composition comprising EPAs.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: February 13, 2018
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventors: Tsuyoshi Harada, Hideo Kanehiro, Kiyoshi Mizuguchi